Product Licensing
Phase IIb/III drug for fatigue in MS patients licensed to Multicell, Inc.
Published in Medical Letter on the CDC and FDA, February 5th, 2006
Multicell will rename LAX- 202 to MCT-125, and will further evaluate MCT-125 in a pivotal phase IIb/III clinical trial which is expected to begin before the end of the 2006.
Multiple sclerosis is an autoimmune disease in which immune cells attack and destroy the myelin sheath protecting neurons in the brain and spinal cord. About two million people worldwide are afflicted with MS, and an estimated 10,000 new MS cases are...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Enterobacter Diagnosis
Method is developed to differentiate thermal-resistant strains of Enterobacter sakazakii - Mutagenicity
In silico screening of chemicals for bacterial mutagenicity has been developed - Preterm Birth
Review examines genetic variation associated with preterm birth - Tuberculosis Therapy
Point mutations in M. tuberculosis genes linked to drug resistance are identified - Water-Borne Illness
Home-based water chlorination reduces diarrhea in HIV-infected Ugandans - Adverse Events
Study refutes link between suicide risk, antidepressants - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
